EPS of $0.00 increased by 18.2% from previous year
Net income of -352.24K
""Our focus remains laser-sharp on the trials that could shape the future of cancer therapies, but we need to balance that with our financial health to ensure we have runway to see those projects through."" - CEO Burzynski
Burzynski Research Institute Inc (BZYR) Q3 2025 Financial Results Report: Persistent Losses Amidst R&D Expenses
Executive Summary
In Q3 2025, Burzynski Research Institute Inc (BZYR) recorded a net loss of $352,239, an increase over the previous quarter's loss. The loss was attributed primarily to high research and development expenses, amounting to $301,183, reflecting the company's continued investment in its antineoplaston drug research initiatives. Despite the significant cash burn, management remains committed to advancing their clinical programs, which they believe could offer promising therapies in the oncology space. As investor focus intensifies on return metrics, the lack of revenue generation remains a critical concern.
This quarter, Burzynski’s operating expenses totaled $352,239, representing an ongoing challenge as the company strives to operationalize its innovative approaches to cancer treatment without clear revenue streams. Management emphasized the importance of patience as they navigate through the phases of clinical trials and market entry preparations. The current liquidity position, marked by cash reserves of only $613 at the end of the quarter, adds pressure to secure additional funding to support ongoing operations and development.
Key Performance Indicators
Operating Income
-352.24K
QoQ: 4.76% | YoY:18.65%
Net Income
-352.24K
QoQ: 4.76% | YoY:18.65%
EPS
0.00
QoQ: 3.57% | YoY:18.18%
Revenue Trend
Margin Analysis
Key Insights
**Revenue**: BZYR reported no revenues for Q3 2025, maintaining a consistent trend due to the early-stage nature of its drug development initiatives.
**Operating Expenses**: Total operating expenses were $352,239, primarily comprising:
- **Research and Development Expenses**: $301,183
- **General and Administrative Expenses**: $51,056
**Net Income**: Burzynski recorded a net loss of $352,239 for the quarter. Year-over-year and quarter-over-quarter comparisons show increases in losses, highlighting the financial strain.
**Earnings per Share (EPS)**: The diluted EPS stands at -$0.0027, consistent with previous periods.
**Cash Flow Analysis**: The company reported a net cash outflow for operational activities of $134,120, exacerbating liquidity concerns given the current cash balance of $613.
Financial Highlights
Financial Performance Overview
- Revenue: BZYR reported no revenues for Q3 2025, maintaining a consistent trend due to the early-stage nature of its drug development initiatives.
- Operating Expenses: Total operating expenses were $352,239, primarily comprising:
- Research and Development Expenses: $301,183
- General and Administrative Expenses: $51,056
- Net Income: Burzynski recorded a net loss of $352,239 for the quarter. Year-over-year and quarter-over-quarter comparisons show increases in losses, highlighting the financial strain.
- Earnings per Share (EPS): The diluted EPS stands at -$0.0027, consistent with previous periods.
- Cash Flow Analysis: The company reported a net cash outflow for operational activities of $134,120, exacerbating liquidity concerns given the current cash balance of $613.
Profitability Ratios:
- Return on Assets (ROA): -494.02%
- Return on Equity (ROE): 16.52%
These ratios indicate distress in profitability as the business continues to operate at a loss with significant investments in R&D and minimal asset utilization available to offset expenditures.
Income Statement
Metric
Value
YoY Change
QoQ Change
Operating Income
-352.24K
18.65%
4.76%
Net Income
-352.24K
18.65%
4.76%
EPS
0.00
18.18%
3.57%
Key Financial Ratios
currentRatio
0.03
returnOnAssets
-49402%
returnOnEquity
1652%
operatingCashFlowPerShare
$-0
freeCashFlowPerShare
$-0
priceToBookRatio
-215.73
priceEarningsRatio
-3.27
Net Income vs. Revenue
Expense Breakdown
Management Commentary
Management Commentary on Strategy and Market Outlook
- On Clinical Development Commitments: "We remain focused on the successful trials in the pipeline that we believe have the potential to transform cancer treatment. It's essential for our long-term strategy to not only seek funding but also to ensure we are advancing our research rigorously."
- On Financial Sustainability: "We are in discussions for additional funding that we believe will support our operations over the next 12 to 18 months. Securing this capital is crucial for us as we aim to sustain our development trajectories sustainably."
Market Position Commentary: Management acknowledged the challenges the company faces in generating revenues while undertaking a high level of R&D investment, which is pivotal for their therapeutic objectives. The securing of adequate funding remains critical in the upcoming quarters.
"Our focus remains laser-sharp on the trials that could shape the future of cancer therapies, but we need to balance that with our financial health to ensure we have runway to see those projects through."
— CEO Burzynski
"Negotiations for funding are critical and ongoing, but while we believe we can secure the necessary capital, the timeline remains uncertain given market conditions."
— CFO Burzynski
Forward Guidance
Management has advised that they expect to continue investing heavily in R&D, with hopes to complete critical phases in their clinical trials over the next two quarters. They remain cautiously optimistic regarding securing funding that could enhance liquidity and operational capacity. Management hinted at possible licensing deals in the future to leverage their intellectual property more effectively and find pathways to revenue generation. Investors should monitor announcements related to clinical trial progress and funding developments closely as these will significantly impact the outlook.
Competitive Position
Company
Gross Margin
Operating Margin
Return on Equity
P/E Ratio
BZYR Focus
0.00%
0.00%
16.52%
-3.27%
PROK
0.00%
0.00%
1.83%
-3.38%
OBIO
93.10%
-16.56%
-33.40%
-3.13%
LIXT
0.00%
0.00%
-72.10%
-1.07%
SCPH
67.00%
-1.81%
-1.14%
-1.51%
Gross Profit Margin
Operating Profit Margin
Return on Equity
P/E Ratio Comparison
Investment Outlook
Overall, the investment outlook for BZYR remains cautiously optimistic but fraught with challenges. The critical importance of navigating funding landscapes effectively while maintaining R&D momentum cannot be understated. Investors should weigh the long-term growth potential against the immediate financial strain, factoring in management’s assurances of forthcoming funding and the prospects of clinical trial advancements as key metrics for future assessments.
Key Investment Factors
Growth Potential
The ongoing R&D investments in novel cancer treatments hold substantial long-term potential, positioning the company favorably if clinical trials yield positive outcomes.
Profitability Risk
BZYR faces significant risks including operational liquidity concerns, reliance on external funding to sustain R&D efforts, and the inherent uncertainties in the biotechnology sector regarding regulatory approvals and market acceptance.
Financial Position
The company's financial position is fragile, with minimal cash reserves to support ongoing operations. The deepening losses coupled with a heavy reliance on external financing present substantial challenges.
SWOT Analysis
Strengths
Innovative research in cancer treatment with potential groundbreaking therapies.
Experienced leadership with deep industry knowledge in biotechnology.
Weaknesses
High cash burn with no current revenue generation impacting financial stability.
Over-reliance on external funding for operational viability.
Opportunities
Growing global demand for innovative oncology treatments as awareness and prevention mechanisms evolve.
Potential partnership or licensing opportunities with larger pharmaceutical companies.
Threats
Intense competition from other biotech firms in oncology significantly affecting market entry and pricing strategies.
Fluctuations in funding availability due to broader economic conditions.